TV 1380

Drug Profile

TV 1380

Alternative Names: Albu-CocH; AlbuBChE; Cocaine hydrolase - Teva; Recombinant human serum albumin mutated butyrylcholinesterase; TV-1380

Latest Information Update: 21 Mar 2016

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator CoGenesys
  • Developer Teva Pharmaceutical Industries
  • Class Antidotes; Cholinesterases; Proteins
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Cocaine abuse

Most Recent Events

  • 21 Mar 2016 No recent reports on development identified - Phase-II for Cocaine abuse in Spain and USA (IM)
  • 01 Oct 2014 Teva Pharmaceutical completes a phase II trial in Cocaine abuse in USA and Spain (NCT01887366)
  • 17 Sep 2013 Phase-II clinical trials in Cocaine abuse in Spain (IM)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top